Company / PP&E (Net)
CRESCENT BIOPHARMA, INC. PP&E (Net) History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$846.0K
FY2025
5-year range
$452.3K / $1.1M
FY2021-FY2025
Trend
-23.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $1M to $846,000 over the past 9 years.
Based on SEC 10-K filings.
$846,000 in FY2025 with a 10-year CAGR of +5.0%.
Declined from $1M to $846,000 over the past 9 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +5.0%
Key checks
Key Insights
- In FY2025, pp&e (net) decreased 23.6% year-over-year.
- Peak pp&e (net) was recorded in FY2017.
- Lowest pp&e (net) in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $846.0K | -23.6% |
| FY2017 | $1.1M | +4.8% |
| FY2016 | $1.1M | +102.6% |
| FY2015 | $521.4K | +15.3% |
| FY2014 | $452.3K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026